Suppr超能文献

用于诊断慢性肝炎肝纤维化的增强肝纤维化评分

Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis.

作者信息

Tamaki Nobuharu, Takaura Kenta, Higuchi Mayu, Yasui Yutaka, Itakura Jun, Tsuchiya Kaoru, Nakanishi Hiroyuki, Izumi Namiki, Kurosaki Masayuki

机构信息

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.

出版信息

Diagnostics (Basel). 2024 Jun 21;14(13):1317. doi: 10.3390/diagnostics14131317.

Abstract

The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas with a high number of elderly people suffering from chronic liver disease has yet to be determined. This is a prospective study that included 373 consecutive patients who underwent a liver biopsy and had their ELF score measured on the same day. The diagnostic accuracy of the ELF score for liver fibrosis and the effect of age on the ELF score were investigated. The median (interquartile) ELF scores in F0, F1, F2, F3, and F4 are 8.7 (8.2-9.2), 9.3 (8.8-10.0), 10.1 (9.4-10.7), 10.7 (9.9-11.2), and 12.0 (11.2-12.7), respectively. ELF scores increased with increasing liver fibrosis stage ( < 0.001). The diagnostic accuracy of the ELF score and FIB-4 for significant fibrosis (F2-4) and advanced fibrosis (F3-4) was comparable, but the ELF score had a higher diagnostic accuracy for cirrhosis (F4) than FIB-4. When patients were stratified by age of 60 years, the median ELF score did not differ by age in F2, F3, and F4. However, the median FIB-4 increased in patients with ≥60 years compared to those with <60 years in all fibrosis stages. : ELF score has high diagnostic accuracy for liver fibrosis, regardless of age, and it could be used as a primary screening method.

摘要

增强肝纤维化(ELF)评分是一项血液检测,它结合了三种与肝纤维化相关的标志物。ELF评分的效用主要在西方国家得到了证实,但在有大量老年慢性肝病患者的地区它是否有用尚未确定。这是一项前瞻性研究,纳入了373例连续接受肝活检并于同一天测量其ELF评分的患者。研究了ELF评分对肝纤维化的诊断准确性以及年龄对ELF评分的影响。F0、F1、F2、F3和F4期的ELF评分中位数(四分位间距)分别为8.7(8.2 - 9.2)、9.3(8.8 - 10.0)、10.1(9.4 - 10.7)、10.7(9.9 - 11.2)和12.0(11.2 - 12.7)。ELF评分随着肝纤维化阶段的增加而升高(<0.001)。ELF评分和FIB - 4对显著纤维化(F2 - 4)和进展性纤维化(F3 - 4)的诊断准确性相当,但ELF评分对肝硬化(F4)的诊断准确性高于FIB - 4。当按60岁年龄分层时,F2、F3和F4期的ELF评分中位数在不同年龄组中无差异。然而,在所有纤维化阶段,≥60岁患者的FIB - 4中位数相较于<60岁患者有所升高。ELF评分对肝纤维化具有较高的诊断准确性,不受年龄影响,可作为一种初步筛查方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e486/11240480/4d0447feff3a/diagnostics-14-01317-g001.jpg

相似文献

1
Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis.
Diagnostics (Basel). 2024 Jun 21;14(13):1317. doi: 10.3390/diagnostics14131317.
4
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002. Epub 2023 Apr 21.
5
Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
Horm Metab Res. 2019 Feb;51(2):134-140. doi: 10.1055/a-0713-1330. Epub 2018 Oct 1.
10
Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort.
Clin Infect Dis. 2013 Jul;57(2):240-6. doi: 10.1093/cid/cit245. Epub 2013 Apr 16.

引用本文的文献

1
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.
Nutrients. 2025 Jun 30;17(13):2189. doi: 10.3390/nu17132189.

本文引用的文献

2
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
3
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
Clin Gastroenterol Hepatol. 2024 Apr;22(4):789-797.e8. doi: 10.1016/j.cgh.2023.11.022. Epub 2023 Dec 2.
4
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.
Quant Imaging Med Surg. 2023 Oct 1;13(10):6493-6502. doi: 10.21037/qims-23-511. Epub 2023 Aug 28.
5
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
Hepatology. 2023 Dec 1;78(6):1858-1866. doi: 10.1097/HEP.0000000000000470. Epub 2023 May 22.
6
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002. Epub 2023 Apr 21.
7
Global burden of hepatitis B virus: current status, missed opportunities and a call for action.
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524-537. doi: 10.1038/s41575-023-00760-9. Epub 2023 Apr 6.
8
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
10
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.
Hepatol Res. 2022 Jun;52(6):497-507. doi: 10.1111/hepr.13764. Epub 2022 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验